Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1,6-diazaspiro(3.4)octane-1-propanenitrile, 3-methyl-beta-oxo-6-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-, (3s,4r)-
2. 3-((3s,4r)-3-methyl-6-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1,6-diazaspiro(3.4)octan-1-yl)-3-oxopropanenitrile
3. Jte-052
1. 1263774-59-9
2. Jte-052
3. Jte-052a
4. Corectim
5. Leo 124249a
6. Leo 124249
7. Leo-124249a
8. Leo-124249
9. Delgocitinib [usan]
10. 9l0q8kk220
11. 3-[(3s,4r)-3-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
12. 3-((3s,4r)-3-methyl-6-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1,6-diazaspiro(3.4)octan-1-yl)-3-oxopropanenitrile
13. 3-[(3s,4r)-3-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxidanylidene-propanenitrile
14. Delgocitinibum
15. Corectim (tn)
16. 3-((3s,4r)-3-methyl-6-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile
17. 3-[(3s,4r)-3-methyl-6-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
18. Ent-60
19. Delgocitinib (jan/usan)
20. Delgocitinib [inn]
21. Delgocitinib [jan]
22. Delgocitinib [who-dd]
23. Unii-9l0q8kk220
24. Gtpl9619
25. Jte052
26. Chembl4297507
27. Schembl12547007
28. Chebi:167600
29. Dtxsid401336933
30. Ex-a5577
31. Bdbm50545650
32. At24880
33. Leo-124249;jte-052
34. Bd178539
35. Hy-109053
36. Cs-0031558
37. D11046
38. A936874
39. 1,6-diazaspiro(3.4)octane-1-propanenitrile, 3-methyl-.beta.-oxo-6-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-, (3s,4r)-
40. 1,6-diazaspiro(3.4)octane-1-propanenitrile, 3-methyl-beta-oxo-6-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-, (3s,4r)-
41. Fhx
| Molecular Weight | 310.35 g/mol |
|---|---|
| Molecular Formula | C16H18N6O |
| XLogP3 | 1.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 2 |
| Exact Mass | 310.15420922 g/mol |
| Monoisotopic Mass | 310.15420922 g/mol |
| Topological Polar Surface Area | 88.9 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 544 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of dermatitis and eczema
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
Details:
Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor. It is indicated for the treatment of Moderate to Severe Chronic Hand Eczema.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: Anzupgo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2024
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LEO Pharma’s Anzupgo® (delgocitinib) Cream Achieves Marketing Approval in Switzerland
Details : Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor. It is indicated for the treatment of Moderate to Severe Chronic Hand Eczema.
Brand Name : Anzupgo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 14, 2024
Details:
Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor. It is indicated for the treatment of Moderate to Severe Chronic Hand Eczema.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: Anzupgo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2024
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Germany Becomes The First Country to Launch LEO Pharma’s Anzupgo® (delgocitinib) Cream
Details : Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor. It is indicated for the treatment of Moderate to Severe Chronic Hand Eczema.
Brand Name : Anzupgo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 15, 2024
Details:
Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor for CHE. It is under clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: Anzupgo
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2024
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Accepts LEO Pharma’s NDA for Delgocitinib Cream for Chronic Hand Eczema
Details : Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor for CHE. It is under clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Brand Name : Anzupgo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 23, 2024
Details:
Anzupgo (delgocitinib) cream is a topical pan-JAK inhibitor. It is indicated for the treatment of adult patients with moderate to severe chronic hand eczema.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: Anzupgo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2024
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EU Approves LEO Pharma’s Anzupgo® For Chronic Hand Eczema in Adults
Details : Anzupgo (delgocitinib) cream is a topical pan-JAK inhibitor. It is indicated for the treatment of adult patients with moderate to severe chronic hand eczema.
Brand Name : Anzupgo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 23, 2024
Details:
Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor for CHE. It is under clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: Anzupgo
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2024
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LEO Pharma Receives Positive CHMP Opinion for Anzupgo® in Hand Eczema Treatment
Details : Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor for CHE. It is under clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Brand Name : Anzupgo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 25, 2024
Details:
LP0133 (delgocitinib) cream is an investigational, first-in-class, topical pan-Janus kinase (JAK) inhibitor for CHE. Under phase 3 clinical development for Moderate to Severe Chronic Hand Eczema.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: LP0133
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LEO Pharma Reports Positive Phase 3 Data from DELTA FORCE Trial in Chronic Hand Eczema
Details : LP0133 (delgocitinib) cream is an investigational, first-in-class, topical pan-Janus kinase (JAK) inhibitor for CHE. Under phase 3 clinical development for Moderate to Severe Chronic Hand Eczema.
Brand Name : LP0133
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 24, 2024
Details:
LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: LP0133
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin d...
Brand Name : LP0133
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 30, 2023
Details:
LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: LP0133
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2023
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin d...
Brand Name : LP0133
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 10, 2023
Details:
LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: LP0133
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin d...
Brand Name : LP0133
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2022
Details:
The agreement will support both LEO Pharma’s strategy of building a simpler and more competitive organization and pipeline including its lead asset LP0133 (delgocitinib) and DKSH Business Unit Healthcare’s strategic focus of strengthening its regional footprint.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: LP0133
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: DKSH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 29, 2022
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : DKSH
Deal Size : Undisclosed
Deal Type : Partnership
Details : The agreement will support both LEO Pharma’s strategy of building a simpler and more competitive organization and pipeline including its lead asset LP0133 (delgocitinib) and DKSH Business Unit Healthcare’s strategic focus of strengthening its regiona...
Brand Name : LP0133
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 29, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
